BOSTON, Mass., November 5, 2026 — Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, today announced the first participant has been dosed in its Phase 2 Vista PD clinical trial evaluating VIM0423 for the treatment of tremor insufficiently responsive to dopaminergic therapy in adults with Parkinson’s disease. The company also […] The post Vima Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial for Parkinson’s Disease Tremor Insufficiently Responsive to Dopaminergic Therapy appeared first on Vima Therapeutics .